Digestery
Longevity supplements › Rapamycin and Aging › Studies

Randomized trial · measured other health measures

48-week trial in healthy adults: weekly rapamycin did not clearly change belly fat

Moel and colleagues · Aging · 2025

Original title: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

Belly fat (main outcome) did not change (p = 0.942). Side effects were similar across groups. Women on 10 mg gained lean tissue (p = 0.013) and reported less pain (p = 0.015).

The study at a glance

Type of study
Randomized trial
Who or what was studied
Healthy adults of normal aging
What was tested
Rapamycin 5 mg or 10 mg once a week, vs placebo, for 48 weeks
What it measured
Several kinds of outcomes
Daily amount
10 mg/week
How long
48 weeks
Trial registration
NCT04488601
Who has a stake
Company stake
Several authors are employees and shareholders of AgelessRx.
Journal
Aging, 2025
Source
PubMed record 40188830. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •The abstract does not say how many people took part.
  • •Lasted 48 weeks.
  • •Measured several kinds of outcomes.
  • –Company stake: Several authors are employees and shareholders of AgelessRx.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer

Few other papers sit on the same step, so there is little to compare it with.

Other papers on the same step

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.